EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition

Paige C Arneson-Wissink iD, Katherine Pelz, Beth Worley, Heike Mendez, Peter Pham, Parham Diba, Peter R Levasseur, Grace McCarthy, Alex Chitsazan, Jonathan R Brody, Aaron J Grossberg iD

Journal of Cachexia, Sarcopenia and Muscle · 2026

DOI: 10.1002/jcsm.70253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Paige C Arneson-Wissink und 10 weiteren Autor:innen. Beteiligte Einrichtung: Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Cachexia, Pancreatic Neoplasms, ELAV-Like Protein 1, Adipose Tissue. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hirshberg Foundation for Pancreatic Cancer Research, NCI NIH HHS, Brenden Colson Center for Pancreatic Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cachexia is defined by chronic loss of fat and muscle, is a frequent complication of pancreatic ductal adenocarcinoma (PDAC) and negatively impacts patient outcomes. Nutritional supplementation cannot fully reverse tissue wasting, and the mechanisms underlying this phenotype are unclear. This work aims to define the relative contributions of catabolism and anabolism to adipose wasting in PDAC‐bearing mice. Human antigen R (HuR) is an RNA‐binding protein recently shown to suppress adipogenesis. We hypothesize that fat wasting results from a loss of adipose anabolism driven by increased HuR activity in adipocytes of PDAC‐bearing mice.

Methods

Adult C57BL/6J mice received orthotopic PDAC cell ( Kras G12D ; p53 R172H/+ ; Pdx1‐cre ) (PDAC) or PBS (sham) injections. Mice exhibiting moderate cachexia (9 days after injection) were fasted for 24 h, or fasted 24 h and refed 24 h before euthanasia. A separate cohort of PDAC mice were treated with an established HuR inhibitor (KH‐3, 100 mg/kg) and subjected to the fast/refeed paradigm. We analysed body mass, gross fat pad mass and adipose tissue mRNA expression. We quantified lipolytic rate as the normalized quantity of glycerol released from 3T3‐L1 adipocytes in vitro and gonadal fat pads (gWAT) ex vivo.

Results

3T3‐L1 adipocytes treated with PDAC cell conditioned media (CM) had lower expression of lipolysis and lipogenesis genes than control cells and did not display elevated lipolysis as measured by liberated glycerol. PDAC gWAT cultured ex vivo displayed decreased lipolysis compared to sham gWAT (−54.7%). PDAC and sham mice lost equivalent fat mass after a 24 h fast; however, PDAC mice could not restore inguinal fat pads (iWAT) (−40.5%) or gWAT (−31.8%) mass after refeeding. RNAseq revealed 572 differentially expressed genes in gWAT from PDAC compared to sham mice. Downregulated genes ( n = 126) were associated with adipogenesis (adj p = 0.05), and expression of adipogenesis master regulators Pparg and Cebpa were reduced in gWAT from PDAC mice. Immunohistochemistry revealed increased HuR staining in gWAT (+74.9%) and iWAT (+41.2%) from PDAC mice. Inhibiting HuR binding restored lipogenesis in refed animals with a concomitant increase in iWAT mass (+131.7%).

Conclusions

Our work highlights deficient adipose anabolism as a driver of reduced lipid content in 3T3‐L1 adipocytes treated with PDAC conditioned media and PDAC mice. The small molecule KH‐3, which disrupts HuR binding, restored adipose anabolism in PDAC mice. This highlights HuR as a potentially targetable regulatory node for adipose anabolism in cancer cachexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaPancreatic NeoplasmsELAV-Like Protein 1Adipose TissueAnimalsMiceHumansCarcinoma, Pancreatic DuctalMaleCell Line, TumorMice, Inbred C57BLDisease Models, AnimalAdipocytesLipolysis

Stichwörter der Autor:innen

HuRadipogenesisadiposecachexiapancreatic ductal adenocarcinoma

Substanzen

ELAV-Like Protein 1

Autor:innen und Institutionen

  • Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Surgery, Oregon Health & Science University, Portland, Oregon, USA.
  • Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.

ORCID-Profile: Paige C Arneson-Wissink, Aaron J Grossberg

Förderung

  • Hirshberg Foundation for Pancreatic Cancer Research
  • NCI NIH HHS
  • Brenden Colson Center for Pancreatic Care
  • AACR Grant
  • Oregon Health and Sciences University
  • NIH HHS
  • Knight Cancer Institute
  • Knight Cancer Institute, Oregon Health and Science University

Zitieren

APA

Arneson-Wissink, P. C., Pelz, K., Worley, B., Mendez, H., Pham, P., Diba, P., Levasseur, P. R., McCarthy, G., Chitsazan, A., Brody, J. R., & Grossberg, A. J. (2026). Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70253

Vancouver

Arneson-Wissink PC, Pelz K, Worley B, Mendez H, Pham P, Diba P, et al. Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70253

BibTeX
@article{ArnesonWissink2026,
  author = {Arneson-Wissink, Paige C and Pelz, Katherine and Worley, Beth and Mendez, Heike and Pham, Peter and Diba, Parham and Levasseur, Peter R and McCarthy, Grace and Chitsazan, Alex and Brody, Jonathan R and Grossberg, Aaron J},
  title = {Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  doi = {10.1002/jcsm.70253}
}
Kostenlos starten →